Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) hit a new 52-week high during trading on Monday after BTIG Research raised their price target on the stock from $35.00 to $40.00. BTIG Research currently has a buy rating on the stock. Castle Biosciences traded as high as $32.82 and last traded at $32.59, with a volume of 87596 shares changing hands. The stock had previously closed at $31.31.
Several other equities research analysts have also recently issued reports on CSTL. Robert W. Baird raised their price objective on shares of Castle Biosciences from $34.00 to $37.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 6th. Stephens restated an “overweight” rating and set a $37.00 price objective on shares of Castle Biosciences in a research report on Tuesday, August 6th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $34.00.
Get Our Latest Stock Analysis on Castle Biosciences
Insiders Place Their Bets
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company boosted its stake in shares of Castle Biosciences by 7.1% in the second quarter. The Manufacturers Life Insurance Company now owns 10,122 shares of the company’s stock valued at $220,000 after purchasing an additional 675 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Castle Biosciences by 10.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,882 shares of the company’s stock valued at $215,000 after purchasing an additional 952 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Castle Biosciences by 6.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 18,034 shares of the company’s stock valued at $400,000 after purchasing an additional 1,131 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in Castle Biosciences by 70.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 5,297 shares of the company’s stock worth $117,000 after acquiring an additional 2,187 shares during the last quarter. Finally, RiverPark Advisors LLC lifted its stake in Castle Biosciences by 362.2% in the first quarter. RiverPark Advisors LLC now owns 2,861 shares of the company’s stock worth $63,000 after acquiring an additional 2,242 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.
Castle Biosciences Stock Up 9.4 %
The business’s 50 day moving average is $28.99 and its 200-day moving average is $24.29. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.12 and a quick ratio of 7.92. The company has a market cap of $945.82 million, a PE ratio of -29.79 and a beta of 1.03.
Castle Biosciences (NASDAQ:CSTL – Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.47. Castle Biosciences had a negative net margin of 1.08% and a negative return on equity of 0.77%. The company had revenue of $87.00 million during the quarter, compared to the consensus estimate of $69.95 million. During the same quarter in the previous year, the firm earned ($0.70) earnings per share. As a group, analysts predict that Castle Biosciences, Inc. will post -0.58 EPS for the current year.
About Castle Biosciences
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
See Also
- Five stocks we like better than Castle Biosciences
- Investing in Commodities: What Are They? How to Invest in Them
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- Compound Interest and Why It Matters When Investing
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- Dividend Capture Strategy: What You Need to Know
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.